In ELEVATE-TN, the addition of Obi to Acala (AO) appeared to improve rates of CR/CRi at 4-year follow-up (AO [30.7%] vs. A [11.2%]), including CR/CRi rates of 32.0% vs. 13.0% for TP53 aberrant CLL and 28.2% versus 12.6% for umIGHV [6]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.